title: Glucocorticoid regulation of atrial natriuretic peptide receptors on cultured endothelial cells.
abstract: Cultured pulmonary artery endothelial (CPAE) cells possess specific high affinity receptors for atrial natriuretic peptide (ANP). CPAE cells were used to investigate the regulation of ANP receptors by glucocorticoids. Treatment of CPAE cells with dexamethasone (1 microM) produced a 69.3 +/- 23% (P less than 0.01) increase in the maximum binding of [125I]ANP to CPAE cells without affecting the affinity of binding. The EC50 for the dexamethasone effect was approximately or equal to 0.5 nM, with a maximum effect at 10 nM. The effect was time dependent and developed over 16-72 h, and it could be inhibited by cycloheximide (0.075 micrograms/ml), indicating a requirement for de novo protein synthesis. The glucocorticoid receptor antagonist RU 486 completely inhibited the dexamethasone effect. In affinity cross-linking experiments, dexamethasone increased the labelling of the ANP-R2, or clearance, receptor, whereas labeling of the ANP-R1 receptor could not be detected. Despite the increase in maximum binding, dexamethasone treatment produced a significant (P less than 0.01) decrease in the ANP-stimulated cyclic GMP response of CPAE cells and no change in the affinity of binding for the truncated ANP analog, atriopeptin I. These results indicate that the dexamethasone effect is mediated through glucocorticoid receptors and may be selective for the nonguanylate cyclase-coupled, or ANP-R2, receptor subtype. This study provides direct evidence for regulation of ANP receptors by steroid hormones.
authors.affiliation: Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston 29425.
authors.forename: K L
authors.initials: KL
authors.lastname: Lanier-Smith
authors.forename: M G
authors.initials: MG
authors.lastname: Currie
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D001345:Autoradiography; D001667:Binding, Competitive; D002478:Cells, Cultured; D003432:Cross-Linking Reagents; D006152:Cyclic GMP / Q000096:biosynthesis; D003907:Dexamethasone / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism*; D005938:Glucocorticoids / Q000502:physiology*; D015735:Mifepristone / Q000494:pharmacology; D010446:Peptide Fragments / Q000378:metabolism; D017461:Receptors, Atrial Natriuretic Factor; D011956:Receptors, Cell Surface / Q000378:metabolism*; D013148:Spironolactone / Q000494:pharmacology
chemical_list: D003432:Cross-Linking Reagents; D005938:Glucocorticoids; D010446:Peptide Fragments; D011956:Receptors, Cell Surface; D013148:Spironolactone; C062525:atrial natriuretic factor prohormone (103-126); D015735:Mifepristone; D003907:Dexamethasone; D009320:Atrial Natriuretic Factor; C062522:atrial natriuretic factor prohormone (103-123); D017461:Receptors, Atrial Natriuretic Factor; D006152:Cyclic GMP